Overview

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.
Phase:
Phase 3
Details
Lead Sponsor:
BioMarin Pharmaceutical
Treatments:
Verapamil